Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Response Biomedical partners Roche Diagnostics for cardiovascular tests

Response Biomedical : 27 June, 2008  (Company News)
Response Biomedical has entered into an agreement granting rights to Roche Diagnostics to market its line of cardiovascular point-of-care (POC) tests worldwide.
Roche Diagnostics' comprehensive sales and marketing infrastructure allows for broad worldwide penetration of Response Biomedical's cardiovascular line.

'We are extremely pleased to partner with Roche Diagnostics, a world leader in clinical diagnostics. Their distribution and marketing capabilities will be strategically important in quickly expanding the reach of our products into the marketplace,' said S Wayne Kay, chief executive officer, Response Biomedical. 'This collaboration significantly enhances our commercialization strategy and sets the stage for rapid market expansion. Furthermore, we are exploring the application of our proprietary RAMP platform to other clinical areas where its unique advantages can be leveraged to improve patient care.'

The RAMP cardiovascular product line includes Troponin I, CK-MB, Myoglobin and NT-proBNP Tests. The company is awaiting US Food and Drug Administration 510(k) clearance before the NT-proBNP Test can be sold in the USA.

'Our collaboration with Response Biomedical Corporation is an important step to further expand our presence in the dynamically growing POC cardiac market, expecting double-digit growth over the coming years,' said Dirk H Ehlers, head of Roche Professional Diagnostics. 'The Roche POC portfolio will be enhanced by the addition of the RAMP cardiovascular product line and will allow us to target key global markets by responding to customer demands for choice in systems for different throughput and parameter needs.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo